Literature DB >> 17519495

Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses.

Sandra C Numan, Peter Veldkamp, Ed J Kuijper, Renate J van den Berg, Jaap T van Dissel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17519495      PMCID： PMC1954844          DOI： 10.1136/gut.2006.119016

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

Review 2.  Alternative treatments for Clostridium difficile disease: what really works?

Authors:  Lynne V McFarland
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

3.  Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients.

Authors:  Renate J van den Berg; Lesla S Bruijnesteijn van Coppenraet; Hendrik-Jan Gerritsen; Hubert P Endtz; Eric R van der Vorm; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 4.  Laboratory diagnosis of Clostridium difficile disease.

Authors:  M Delmée
Journal:  Clin Microbiol Infect       Date:  2001-08       Impact factor: 8.067

Review 5.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

6.  Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

Authors:  Jaap T van Dissel; Nanda de Groot; Charles Mh Hensgens; Sandra Numan; Ed J Kuijper; Peter Veldkamp; Jan van 't Wout
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

7.  The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.

Authors:  Karen W H Young; Ian C Munro; Steve L Taylor; Peter Veldkamp; Jaap T van Dissel
Journal:  Regul Toxicol Pharmacol       Date:  2007-02-12       Impact factor: 3.271

8.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

Review 9.  Clostridium difficile infection: responses, relapses and re-infections.

Authors:  M H Wilcox; R C Spencer
Journal:  J Hosp Infect       Date:  1992-10       Impact factor: 3.926

10.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.

Authors:  W A Knaus; D P Wagner; E A Draper; J E Zimmerman; M Bergner; P G Bastos; C A Sirio; D J Murphy; T Lotring; A Damiano
Journal:  Chest       Date:  1991-12       Impact factor: 9.410
  10 in total
  19 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

Review 4.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

5.  Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.

Authors:  Jerlyn K Sponseller; Jennifer A Steele; Diane J Schmidt; Hyeun Bum Kim; Gillian Beamer; Xingmin Sun; Saul Tzipori
Journal:  J Infect Dis       Date:  2014-11-07       Impact factor: 5.226

Review 6.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

7.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

Review 8.  Intestinal carriage of Staphylococcus aureus: how does its frequency compare with that of nasal carriage and what is its clinical impact?

Authors:  D S Acton; M J Tempelmans Plat-Sinnige; W van Wamel; N de Groot; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-08       Impact factor: 3.267

Review 9.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.